Early Goal Directed Therapy in Septic Shock

Revised and reviewed 14 February 2014

OVERVIEW

Early Goal Directed Therapy (EGDT) definition

  • Within 6 hours of presentation to the Emergency Department intensive monitoring of specific circulatory parameters with the aggressive management of 5 key parameters to specified targets to optimise oxygen delivery to tissues.

Parameters

  1. CVP  8-12 mmHg
  2. MAP 65 – 90 mmHg
  3. Urine output >0.5 ml/kg/hr
  4. Mixed venous oxygen saturation >65% / ScvO2 >70%
  5. Haematocrit >30%

Interventions

  1. Reduce work of breathing by early use of mechanical ventilation
  2. Fluid resuscitation
  3. Use of vasoactive agents: noradrenaline, dobutamine
  4. Transfusion

See the Rivers et al, 2001 EGDT protocol here (figure 2 from the article).

RATIONALE

The rationale for EGDT is that early optimization of O2 delivery will improve outcome in sepsis

  • evidence supporting use found by the landmark Rivers Trial (NEJM, 2001) that showed a 16% mortality reduction when ScvO2 monitoring added to standard resuscitation target, although patients in treatment arm received more dobutamine and RBCs transfusion as well.

The principle of applying EGDT for septic shock is based on the observations that:

  • Early treatment for Myocardial Infarction, Acute Ischaemic Stroke and Trauma improves patient outcomes
  • Patients presenting to ED with sepsis have measurable O2 deficit
  • O2 deficit is evidenced by high lactate and high ScvO2
  • For septic shock the hypothesis is that early optimization of the compromised septic circulation may reduce mortality

ARGUMENTS FOR

  • sensible end-point for O2 delivery as ScvO2 reflects supply-demand balance
  • our patients all have CVL in situ (in the ICU, not necessarily in the ED)
  • Rivers trial showed a substantial reduction in mortality with ScvO2 monitoring vs standard care
  • no other O2 delivery end point has been validated
  • recommended in Surviving Sepsis Guidelines
  • ScvO2 readily available
  • ScvO2 can have continuous monitoring
  • ScvO2 responds to therapy
  • ScvO2  is predictive of outcomes

ARGUMENTS AGAINST

Protocols for implementing EGDT usually result in more fluid being administered, more use of vasoactive medication and more use of blood transfusion which may lead to:

  •  Fluid overload (e.g. APO, abdominal compartment syndrome, edematous tissues impedding oxygen flux to cells)
  • Arrhythmias and myocardial necrosis from inotropes
  • Adverse effects of blood transfusion
  • Effects of excessive oxygen delivery

Evidence (see below for more details)

  • Rivers has numerous inherent flaws
  • EGDT established in ED population but not validated in ICU
  • Australasian sepsis mortality significantly less than Rivers base line and we don’t practice EDGT
  • the only evidence where there is clear time dependent mortality benefit is time to appropriate antibiotic therapy (Kumar et al) — see Antibiotic Timing
  • lactate clearance shown to be non-inferior to continuous ScvO2 monitoring (Jones et al, 2010)

End-points (which parameter, and which value) are numerous and essentially arbitrary

  • PCWP
  • CVP
  • systolic pulse pressure variation
  • pulse pressure variation
  • stroke volume variation
  • MAP
  • HR
  • SVRI
  • Q
  • SV
  • SpO2
  • Hb/HCT
  • DO2
  • GEDV
  • EVLW
  • ITLV
  • urine output
  • serum lactate

Endpoints based on cardiac output and other macrovascular parameters may not be very important

  • macrovascular flow doesn’t mean microvascular flow
  • changes in sepsis (microvascular thrombi with endothelial dysfunction)
  • impaired autoregulation
  • microflow is linked to outcomes
  • microflow can be manipulated (dobutamine)

Proscriptive targets may not suit all (eg higher MAP needed for elderly patients, lower MAP and Hct targets for young, fit patients)

EVIDENCE

The evidence for the intervention is based on:

  • an American, single-centre RCT (Rivers 2001)
  • a recent Chinese multicenter study supporting EGDT
  • Surviving Sepsis Guidelines: Grade 1C (inconsistent results, well done observational studies/control RCTs) recommendation

Limitations of Rivers study include the following:

  • Study population limited to ED presentations and did not include ward patients
  • Single centre
  • Non-blinded
  • Control group had an above-average mortality rate and patients had high rates of comorbidities
  • ‘Rivers effect’ (undivided attention of a critical care trained doctor in the intervention arm)
  • Unclear which interventions are most important – whole EGDT protocol or one single component
  • Target parameters are restrictive
  • Use of ScvO2 and pressure monitoring has not been tested in the target population
  • Transfusion target to improve DO2 contradicts restrictive transfusion practice and may be associated with increased mortality in the critically ill

Other approaches

  • there is clear evidence from meta-analysis(Jones et al, 2008) that quantitative resuscitation within 24 hours, including approaches other than EGDT, improve mortality
  • targeting lactate clearance is non-inferior to EGDT Jones et al, 2010)

Results of Australasian ARISE and related international studies (US ProCESS and UK ProMISE) Awaited

AN APPROACH

  • start early
  • optimize filling (dynamic tests of Starling curve: fluid responsiveness, swing)
  • best fluid controversial (not HES!)
  • optimise O2 carrying capacity
  • optimise oxygenation
  • optimize haemodynamics
  • augment contractility
  • can titrate to an end-point (ScvO2 or lactate) but it may not matter
  • await further higher quality evidence (e.g. ARISE, PROMISE and PROCESS)
  • We don’t use continuous ScVO2 monitoring

OXYGEN DELIVERY AND EXTRACTION

Oxygen delivery is determined by the content of the blood and cardiac output:

  • PaO2 (PAO2, PaCO2, RQ, atmospheric pressure, K)
  • SpO2
  • Hb (affinity of Hb for O2)
  • Q

Mechanisms that sustain oxygen flux

  • increased oxygen delivery (reflex mechanisms, redirection to essential organs)
  • increased extraction ratio
  • reduced VO2 (oxygen conservation behaviours)
  • anaerobic metabolism
  • regional variations
  • chronic adaptation

Predicting microvascular flow

  • clinical examination
  • haemodynamics
  • cardiac output based
  • clinical ‘tissue perfusion’ indicators
  • lactate
  • sublingual capillary flow
  • SmvO2
  • ScvO2
  • O2 extraction ratio
  • central-toe temperature gradient
  • gastric tonometry

ScvO2

  • higher extraction suggest stress
  • < 40-50% implies tissue dysoxia (high extraction)
  • samples upper body venous return largely
  • predictive of post op complications and mortality
  • suggested target: 65-70%

References and Links

LITFL

Journal articles and textbooks

  • Dellinger RP, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 Jan;36(1):296-327. Erratum in: Crit Care Med. 2008 Apr;36(4):1394-6. PubMed PMID: 18158437. [Fulltext]
  • Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010 Feb 24;303(8):739-46. PubMed PMID: 20179283; PubMed Central PMCID: PMC2918907.
  • Jones AE, Brown MD, Trzeciak S, Shapiro NI, Garrett JS, Heffner AC, Kline JA; Emergency Medicine Shock Research Network investigators. The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: a meta-analysis. Crit Care Med. 2008 Oct;36(10):2734-9. Review. PubMed PMID: 18766093; PubMed Central PMCID: PMC2737059.
  • McKenna M. Controversy swirls around early goal-directed therapy in sepsis: pioneer defends ground- breaking approach to deadly disease. Ann Emerg Med. 2008 Dec;52(6):651-4. PubMed PMID: 19048659. [Fulltext]
  • Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77. PubMed PMID: 11794169. [Fulltext]

FOAM and web resources


CCC 700 6

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at the Alfred ICU in Melbourne. He is also the Innovation Lead for the Australian Centre for Health Innovation at Alfred Health and Clinical Adjunct Associate Professor at Monash University. He is a co-founder of the Australia and New Zealand Clinician Educator Network (ANZCEN) and is the Lead for the ANZCEN Clinician Educator Incubator programme. He is on the Board of Directors for the Intensive Care Foundation and is a First Part Examiner for the College of Intensive Care Medicine. He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives.

After finishing his medical degree at the University of Auckland, he continued post-graduate training in New Zealand as well as Australia’s Northern Territory, Perth and Melbourne. He has completed fellowship training in both intensive care medicine and emergency medicine, as well as post-graduate training in biochemistry, clinical toxicology, clinical epidemiology, and health professional education.

He is actively involved in in using translational simulation to improve patient care and the design of processes and systems at Alfred Health. He coordinates the Alfred ICU’s education and simulation programmes and runs the unit’s education website, INTENSIVE.  He created the ‘Critically Ill Airway’ course and teaches on numerous courses around the world. He is one of the founders of the FOAM movement (Free Open-Access Medical education) and is co-creator of litfl.com, the RAGE podcast, the Resuscitology course, and the SMACC conference.

His one great achievement is being the father of two amazing children.

On Twitter, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.